Nanobiotix S.A. NBTX

Company Overview

Nanobiotix S.A. is a France-based clinical-stage biotechnology company focused on developing nanomedicine therapies designed to improve cancer treatment outcomes. The company operates primarily within the oncology and radiotherapy sectors, with a strategic emphasis on enhancing the effectiveness of radiation therapy through proprietary nanoparticle technology platforms. Its lead product candidate, NBTXR3, is a radioenhancer composed of hafnium oxide nanoparticles that are intended to increase tumor sensitivity to ionizing radiation while limiting damage to surrounding healthy tissue.

The company’s primary revenue drivers currently consist of collaboration agreements, licensing arrangements, and research partnerships, as Nanobiotix has not yet established broad commercial product sales. Nanobiotix serves oncology treatment providers, cancer centers, and biopharmaceutical collaborators across multiple cancer indications, including head and neck cancer, soft tissue sarcoma, lung cancer, and pancreatic cancer. Founded in 2003 in Paris, the company evolved from an early-stage nanotechnology research venture into a publicly traded biotechnology company listed on Euronext Paris and the Nasdaq Global Market under the ticker NBTX. Its positioning is differentiated by its physics-based therapeutic approach that seeks to work across multiple solid tumor indications independent of specific genetic biomarkers.

Business Operations

Nanobiotix organizes its operations around the development and clinical advancement of its proprietary NBTXR3 platform. The company generates revenue primarily through strategic licensing and co-development agreements, milestone payments, and collaborative research arrangements. Clinical development activities are conducted across Europe, the United States, and parts of Asia through partnerships with hospitals, academic institutions, and oncology networks. Nanobiotix maintains a significant focus on clinical trial execution, regulatory advancement, and intellectual property expansion related to nanoparticle-enabled radiotherapy enhancement.

A major component of the company’s operational strategy is its global collaboration with Johnson & Johnson Innovative Medicine through subsidiary Janssen Pharmaceutica NV, which involves co-development and commercialization rights associated with NBTXR3 in certain territories and indications. Nanobiotix also controls intellectual property related to nanoparticle engineering and radioenhancement technologies. The company’s operational infrastructure includes clinical research management, translational medicine capabilities, and regulatory coordination activities supporting multinational oncology studies.

Strategic Position & Investments

Nanobiotix’s strategic direction centers on expanding the clinical applicability of NBTXR3 across multiple solid tumors and combining the platform with immunotherapy and checkpoint inhibitor treatments. The company has prioritized late-stage oncology development programs and strategic collaborations intended to accelerate regulatory approval pathways and broaden geographic commercialization opportunities. Its development strategy reflects increasing industry interest in therapies that enhance existing cancer treatment modalities rather than replacing them outright.

One of the company’s most significant strategic transactions was its licensing and collaboration agreement with Johnson & Johnson Innovative Medicine, which included upfront payments, potential milestone-based compensation, and shared development responsibilities. Nanobiotix has also invested heavily in intellectual property protection and translational oncology research. Emerging areas of focus include combinations of radioenhancers with immuno-oncology agents and expansion into difficult-to-treat tumor categories where radiation remains a core therapeutic approach. Public disclosures indicate continued emphasis on advancing registrational studies and strengthening global oncology partnerships.

Geographic Footprint

Nanobiotix is headquartered in Paris, France, and maintains operational and clinical development activities across Europe and North America, including a presence in the United States. The company has conducted or supported clinical trials in multiple international markets and collaborates with healthcare institutions and oncology specialists across several regions. Its shares trade publicly in both France and the United States, supporting access to European and U.S. capital markets.

The company’s strategic partnerships have expanded its international reach into additional territories, including parts of Asia-Pacific through licensing arrangements and multinational oncology studies. Nanobiotix’s operational influence is strongest in markets with advanced radiotherapy infrastructure and active oncology research ecosystems. Its development programs are structured to support future commercialization opportunities in major global cancer treatment markets.

Leadership & Governance

Nanobiotix was co-founded by Laurent Levy, who has played a central role in shaping the company’s long-term strategy and scientific-commercial positioning. Leadership has consistently emphasized innovation in nanomedicine, clinical validation through global oncology trials, and strategic partnerships with larger pharmaceutical organizations to scale development and commercialization capabilities. Governance oversight includes a board structure aligned with French corporate governance standards applicable to publicly listed biotechnology companies.

Key executives include:

• Laurent Levy – Co-Founder and Chairman of the Executive Board
• Mehdi Abbar – Chief Operating Officer
• Anna Karmann – Chief Medical Officer
• Philippe Mauberna – Chief Financial Officer
• Damien Leclerc – Chief Business Officer

Public company filings and investor communications indicate that management’s strategic vision is centered on establishing NBTXR3 as a broadly applicable radioenhancer platform across multiple oncology indications while leveraging international partnerships to support clinical development and eventual commercialization.